Immatics' PRAME Cell Therapy Induces Deep Remission in Pediatric Cancer Patient with No Other Options

summarizeSummary

Immatics N.V. announced positive clinical data for its PRAME-directed cell therapy, showing deep and durable remission in a pediatric patient with advanced nephroblastoma who had exhausted all other treatment options. This data will be presented as a late-breaking poster at the AACR Annual Meeting 2026.

check_boxKey Events

• Deep and Durable Remission Achieved

  A 17-year-old pediatric patient with advanced, rapidly progressing nephroblastoma, who had exhausted all available treatment options, achieved deep remission with marked regression of liver, lung, and brain metastases. The response is ongoing at six months of follow-up, with liquid biopsy showing molecular remission.

• PRAME-Directed Cell Therapy Utilized

  The treatment involved an individual experimental attempt using a PRAME-directed cell therapy engineered with Immatics' PRAME T-cell receptor (IMA203CD8 lentiviral vector).

• Late-Breaking AACR Presentation

  The abstract highlighting this patient case has been accepted for a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.

• Potential for Pediatric Clinical Development

  Immatics is planning to evaluate its PRAME TCR T-cell therapy candidates in pediatric patients with cancer and is assessing options for clinical development, including a potential first-in-pediatrics Phase 1/2 basket study.

auto_awesomeAnalysis

This filing reports highly encouraging clinical data for Immatics' PRAME-directed cell therapy, demonstrating a deep and durable remission in a pediatric patient with advanced, rapidly progressing nephroblastoma who had exhausted all other treatment options. The marked regression of liver, lung, and brain metastases, alongside molecular remission, highlights the significant therapeutic potential of the PRAME platform in a challenging patient population. While a single-patient case, the profound response in a terminal setting is a strong signal for the company's technology and could pave the way for new clinical development in pediatric oncology, as indicated by Immatics' plans for a potential Phase 1/2 basket study.